One Wealth Advisors LLC raised its holdings in shares of Edwards Lifesciences Co. (NYSE:EW – Get Ranking) by 20.7% within the third quarter, in line with the corporate in its most up-to-date disclosure with the Securities and Change Fee (SEC). The fund owned 7,892 shares of the medical analysis firm’s inventory after buying an extra 1,355 shares in the course of the interval. One Wealth Advisors LLC’s holdings in Edwards Lifesciences have been value $652,000 as of its most up-to-date SEC submitting.
→ Merchants Rave: This Is The Greatest Play For Choices! (From Tradewins)
A number of different institutional buyers have additionally not too long ago added to or decreased their stakes in EW. Bogart Wealth LLC purchased a brand new place in shares of Edwards Lifesciences in the course of the third quarter value about $25,000. MV Capital Administration Inc. lifted its holdings in Edwards Lifesciences by 74.1% within the third quarter. MV Capital Administration Inc. now owns 329 shares of the medical analysis firm’s inventory value $27,000 after buying an extra 140 shares in the course of the interval. SouthState Corp acquired a brand new stake in Edwards Lifesciences within the second quarter value about $34,000. Wagner Wealth Administration LLC acquired a brand new stake in Edwards Lifesciences within the second quarter value about $44,000. Lastly, Legacy CG LLC acquired a brand new stake in Edwards Lifesciences within the second quarter value about $48,000. Institutional buyers personal 80.35% of the corporate’s inventory.
Edwards Lifesciences Buying and selling Down 2.0 %
NYSE EW traded down $1.57 throughout buying and selling hours on Friday, hitting $76.01. 1,891,864 shares of the corporate’s inventory have been exchanged, in comparison with its common quantity of three,378,446. The inventory has a 50-day easy shifting common of $77.01 and a 200 day easy shifting common of $81.76. The agency has a market cap of $46.24 billion, a price-to-earnings ratio of 31.80, a PEG ratio of 4.39 and a beta of 1.00. The corporate has a present ratio of three.03, a fast ratio of two.17 and a debt-to-equity ratio of 0.10. Edwards Lifesciences Co. has a 1-year low of $67.13 and a 1-year excessive of $131.10.
Edwards Lifesciences (NYSE:EW – Get Ranking) final introduced its quarterly earnings outcomes on Tuesday, January thirty first. The medical analysis firm reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.03. Edwards Lifesciences had a return on fairness of 26.05% and a web margin of 28.27%. The enterprise had income of $1.35 billion for the quarter, in comparison with analyst estimates of $1.33 billion. Throughout the identical quarter within the prior 12 months, the corporate earned $0.51 earnings per share. The corporate’s quarterly income was up 1.5% on a year-over-year foundation. On common, equities analysts forecast that Edwards Lifesciences Co. will publish 2.52 EPS for the present fiscal 12 months.
Insiders Place Their Bets
In different information, Director Heisz Leslie Stone bought 9,671 shares of Edwards Lifesciences inventory in a transaction on Thursday, February sixteenth. The inventory was bought at a mean worth of $76.82, for a complete worth of $742,926.22. Following the completion of the transaction, the director now instantly owns 27,480 shares within the firm, valued at $2,111,013.60. The sale was disclosed in a doc filed with the SEC, which is offered by the SEC web site. In associated information, Director Heisz Leslie Stone bought 9,671 shares of Edwards Lifesciences inventory in a transaction on Thursday, February sixteenth. The inventory was bought at a mean worth of $76.82, for a complete transaction of $742,926.22. Following the completion of the sale, the director now owns 27,480 shares of the corporate’s inventory, valued at $2,111,013.60. The transaction was disclosed in a submitting with the Securities & Change Fee, which is offered by this hyperlink. Additionally, VP Daveen Chopra bought 4,000 shares of Edwards Lifesciences inventory in a transaction on Wednesday, February fifteenth. The shares have been bought at a mean worth of $76.01, for a complete worth of $304,040.00. Following the sale, the vp now instantly owns 18,911 shares of the corporate’s inventory, valued at roughly $1,437,425.11. The disclosure for this sale could be discovered right here. Insiders bought 101,471 shares of firm inventory valued at $7,822,864 over the past ninety days. 1.29% of the inventory is presently owned by insiders.
Wall Avenue Analyst Weigh In
EW has been the topic of a variety of analyst studies. TheStreet lowered shares of Edwards Lifesciences from a “b-” ranking to a “c+” ranking in a analysis notice on Friday, November 4th. Citigroup dropped their goal worth on Edwards Lifesciences from $99.00 to $92.00 and set a “purchase” ranking on the inventory in a report on Monday, December twelfth. Truist Monetary upped their goal worth on Edwards Lifesciences from $85.00 to $86.00 and gave the corporate a “purchase” ranking in a report on Wednesday, February 1st. StockNews.com upgraded Edwards Lifesciences from a “maintain” ranking to a “purchase” ranking in a report on Thursday. Lastly, Mizuho dropped their worth goal on Edwards Lifesciences from $100.00 to $85.00 and set a “purchase” ranking on the inventory in a report on Wednesday, December seventh. One analyst has rated the inventory with a promote ranking, 9 have given a maintain ranking and ten have issued a purchase ranking to the corporate. Based mostly on information from MarketBeat.com, the corporate presently has a mean ranking of “Maintain” and a mean goal worth of $89.74.
Edwards Lifesciences Firm Profile
Edwards Lifesciences Corp. engages in patient-focused medical improvements for coronary heart illness and important care monitoring. Its merchandise are categorized into 4 essential areas: Transcatheter Aortic Valve Alternative, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Coronary heart, and Crucial Care.
Additional Studying
Wish to see what different hedge funds are holding EW? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Edwards Lifesciences Co. (NYSE:EW – Get Ranking).
This on the spot information alert was generated by narrative science know-how and monetary information from MarketBeat with a purpose to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial group previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.
Earlier than you take into account Edwards Lifesciences, you will need to hear this.
MarketBeat retains monitor of Wall Avenue’s top-rated and finest performing analysis analysts and the shares they suggest to their purchasers every day. MarketBeat has recognized the 5 shares that prime analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Edwards Lifesciences wasn’t on the listing.
Whereas Edwards Lifesciences presently has a “Maintain” ranking amongst analysts, top-rated analysts consider these 5 shares are higher buys.
View The 5 Shares Right here
20 Shares to Promote Now
MarketBeat has simply launched its listing of 20 shares that Wall Avenue analysts hate. These firms might seem to have good fundamentals, however prime analysts odor one thing critically rotten. Are any of those firms lurking round your portfolio? Discover out by coming into your e mail tackle beneath.
